Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Licenses RT-PCR for Thermal Cyclers

NEW YORK, June 23 (GenomeWeb News) - Cepheid has expanded its license to Applera's core PCR patents to include real-time PCR for applications in thermal cyclers, the companies said today.

Cepheid has obtained a non-exclusive global license to make, use, and sell its SmartCycler and GeneXpert brand thermal cyclers, as well as other Cepheid thermal cyclers, using Applera's real-time PCR technology.

Additionally, with a payment of $11.5 million over a two-year period, Cepheid expands its rights under its existing thermal-cycler supplier agreement with Applera to include human diagnostics but not HIV and Hepatitis C applications.

 

The licensing deal was announced as Applera's Applied Biosystems group obtained injunctions to halt the manufacture and sale of RT-PCR thermal cyclers by a group of companies. For details, click here.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.